1. Home
  2. FEBO vs IMNN Comparison

FEBO vs IMNN Comparison

Compare FEBO & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fenbo Holdings Limited

FEBO

Fenbo Holdings Limited

N/A

Current Price

$1.02

Market Cap

10.5M

Sector

N/A

ML Signal

N/A

Logo Imunon Inc.

IMNN

Imunon Inc.

HOLD

Current Price

$1.84

Market Cap

8.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FEBO
IMNN
Founded
1993
1982
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.5M
8.4M
IPO Year
2022
2000

Fundamental Metrics

Financial Performance
Metric
FEBO
IMNN
Price
$1.02
$1.84
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
41.5K
52.7K
Earning Date
05-12-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.61
$0.48
52 Week High
$1.46
$9.32

Technical Indicators

Market Signals
Indicator
FEBO
IMNN
Relative Strength Index (RSI) 48.74 23.14
Support Level $0.68 N/A
Resistance Level $1.28 $2.50
Average True Range (ATR) 0.11 0.14
MACD 0.01 0.00
Stochastic Oscillator 45.57 13.92

Price Performance

Historical Comparison
FEBO
IMNN

About FEBO Fenbo Holdings Limited

Fenbo Holdings Ltd is a company engaged in producing premium personal care electric appliances, principally electrical hair styling products such as straighteners, curlers, trimmers, etc., and toy products to overseas markets. It manufactures and sells products such as Straightener, Mini Straightener, and Curling Iron.

About IMNN Imunon Inc.

Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit an immunological response. The company's clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer.

Share on Social Networks: